QANDLI DIABET 2 TUR BEMORLARINI DAVOLASHDA GO'P-1 AGONISTINING O‘RNI
DOI:
https://doi.org/10.47390/Med-pro/v3i5y2025/N02Ключевые слова:
Glyukagonga o‘xshash peptid 1 (GO‘P-1); Qandli diabet; Insulinrezistentlik; Postprandial glikemiya; Semizlik.Аннотация
Hozirgi kunda endokrinologiya sohasidagi asosiy yutuqlaridan biri qandli diabet 2 tur (QD) bilan og‘rigan bemorlarni davolashga bir qancha yangi guruhdagi gipoglikemik dori vositalarining paydo bo‘lishidir. Bularga glukagonga o‘xshash peptid-1 (GO‘P-1) retseptorlari agonistlari, natriy-glyukoza kotransporter-2 (SGLT-2) ingibitorlari va dipeptidil peptidaza 4 (DPP-4) ingibitorlari kiradi. Ularning dastlabki ikkitasini bir qator yirik randomizatsiyalangan tadqiqot sinovlarida o‘rganilganda, qandli diabet 2 tur bilan og‘rigan bemorlarda yurak-qon tomir kasalliklari va umumiy o‘lim ko‘rsatkichiga, buyrak asoratlari rivojlanish xavfi va boshqa bir qator holatlarga ijobiy ta'sirlari qayd etildi. Ayniqsa GO‘P-1 agonistlari oshqozon-ichak tizimida ovqatdan keyin ishlab chiqariladigan gormonlar GIP va GO‘P-1 singari ta’sir qiladi. Bunda ovqatdan keyingi insulin chiqarilishini oshiradi, ishtaxani kamaytiradi, insulinrezistentlikni kamaytiradi shu orqali qonda glyukoza miqdorini pasaytiradi va tana vaznini kamaytiradi.
Библиографические ссылки
1. Багрий А.Э., Супрун Е.В., Михайличенко Е.С. и др. Хроническая сердечная недостаточность и сахарный диабет 2 типа: состояние проблемы. Российский кардиологический журнал 2020;25(4):79 85 [Bagriy A, Suprun Y, Mykhailichenko Iet al. Chronic heart failure and type 2 diabetes: state of the problem. Russian Journal of Cardiology 2020;25(4):3858. (In Russ.)]
2. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375(4):311-22.
3. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020;98(4):839-48
4. Hunt JE, Holst JJ, Jeppesen PB, et al. GLP-1 and intestinal diseases. Biomedicines 2021;9(4):383
5. Лекции по внутренним болезням в период пандемии COVID-19. Учебное пособие. Под ред. Игнатенко Г.А., Багрий А.Э., Оприщенко А.А. Донецк; 2021 [Lectures on internal diseases during the COVID-19 pandemic. Ed. Ignatenko G.A., Bagriy A.E., Oprishchenko A.A. Donetsk; 2021 (In Russ.)].
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375(19):1834-44
7. C. de Jonge, S. Fuentes, E. G. Zoetendal, N. D. Bouvy, R. Nelissen, W. A. Buurman, J. W. Greve, W. M. de Vos & S. S. Rensen. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. International Journal of Obesity volume 43, pages2509–2517 (2019).
8. Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, Jan W Eriksson, Simon Heller , Ole Holm Hels, Richard Pratley, Thozhukat Sathyapalan, Cyrus Desouza; Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527.
9. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41(3):407-77.
10. Qiyuan Keith Liu. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24:15:1431292.
11. О.Е. Супрун, А.Э. Багрий, Е.С. Михайличенко, М.Е. Кривущева. Агониcты рецепторов глюкагоноподобного пептида-1: возможности применения для лечения больных сахарным диабетом 2 типа. КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2022, 31 (2)
12. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a system atic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7(10):776-85
13. Kalyani RR. Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. N Engl J Med 2021;384(13):1248–60
14. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102.
15. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27(4):740-56.
